Clovis Oncology posts $160M loss for 2014 fiscal year

BOULDER — Clovis Oncology Inc. (Nasdaq: CLVS) on Wednesday reported a loss for its fourth quarter and fiscal year 2014 that ended Dec. 31, but its chief executive said 2015 is shaping up to be a pivotal year for the Boulder-based company that is developing drugs, including those that could treat lung and ovarian cancer.

Clovis reported a net loss for the fourth quarter of $54.9 million, or $1.62 per share, and $160 million, or $4.72 per share, for the year. This compares to a net loss of $29.2 million, 92 cents per share for the fourth quarter…